deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 10-arm NCT03162536

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Conditions Chronic Lymphocytic Leukemia Diffuse Large B Cell Lymphoma Follicular Lymphoma Lymphoma, B-Cell Mantle Cell Lymphoma Marginal Zone Lymphoma Richter's Transformation Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia
Interventions Nemtabrutinib
Updated 30 times since 2017 Last updated: Sep 1, 2025 Started: Jun 26, 2017 Primary completion: Sep 18, 2026 Completion: Sep 18, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03162536, this PHASE1/PHASE2 trial focuses on Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma and remains ongoing. Sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), it has been updated 30 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2019 · 16 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Oct 2025 · 10 months · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

30 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Dec 2024 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 25 earlier versions

  1. Feb 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  14. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  16. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  19. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  20. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  21. Oct 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  22. Jun 2018 — Oct 2019 [monthly]

    Recruiting PHASE1

  23. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  24. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  25. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Data source: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations